Braidwell LP Has $19.49 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Braidwell LP boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 36.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,239,770 shares of the biopharmaceutical company's stock after acquiring an additional 596,000 shares during the quarter. Braidwell LP owned about 1.44% of Ocular Therapeutix worth $19,486,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of OCUL. Knoll Capital Management LLC lifted its holdings in shares of Ocular Therapeutix by 199.6% in the 3rd quarter. Knoll Capital Management LLC now owns 600,400 shares of the biopharmaceutical company's stock valued at $5,223,000 after buying an additional 400,000 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter worth $544,000. FMR LLC boosted its position in shares of Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company's stock worth $3,779,000 after purchasing an additional 428,335 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Ocular Therapeutix by 11.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 130,202 shares of the biopharmaceutical company's stock worth $1,133,000 after purchasing an additional 13,238 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Ocular Therapeutix by 146.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company's stock valued at $9,661,000 after purchasing an additional 660,080 shares in the last quarter. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the transaction, the insider now owns 269,059 shares of the company's stock, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on OCUL. HC Wainwright boosted their price objective on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Scotiabank initiated coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 price target on the stock. Finally, Robert W. Baird dropped their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $16.71.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock traded down $0.17 during mid-day trading on Friday, hitting $9.89. 775,830 shares of the company were exchanged, compared to its average volume of 1,828,064. Ocular Therapeutix, Inc. has a 12-month low of $2.44 and a 12-month high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The company has a market capitalization of $1.55 billion, a P/E ratio of -7.49 and a beta of 1.26. The business's 50 day simple moving average is $9.98 and its two-hundred day simple moving average is $8.25.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.